Samsung Biologics
OverviewSuggest Edit
Samsung Biologics is a contract development and manufacturing organization. It provides cell-line development to commercial manufacturing of drug substances and products. The company offers cGMP (Current Good Manufacturing Practice) facilities providing clinical and commercial products based on mammalian cell culture.
| Type | Public | |
| Founded | 2011 | |
| HQ | KR | Map |
| Website | samsungbiologics.com | |
| Employee Ratings | More |
Recent NewsAll News
- Samsung Biologics drives digital transformation with Plant 4 Virtual Showroom launch
- $ 25,497.26 MN Biopharmaceuticals Contract Manufacturing Market 2020: Top Companies Samsung Biologics, Inno Biologics Ventures, Ajinomoto, WuXi Biologics
- Samsung Biologics inks development partnership with Dinona for potential COVID-19 treatment
- Samsung Biologics signs strategic partnership with Kanaph Therapeutics to develop treatment for retinal diseases
Key People/Management at Samsung Biologics
John Rim
President & CEO
Dong Joong Kim
Senior Vice President & Managing Director
Seok Woo Jeong
Independent Director
Jo Kwon
Independent Director
Kun Nyoung
Independent Director
Eunice Kyunghee Kim
Independent Director
Samsung Biologics Financials and Metrics
Samsung Biologics Revenue
Market capitalization (21-Jan-2021) | 52.5t |
Closing stock price (21-Jan-2021) | 796.0k |
Samsung Biologics's current market capitalization is ₩52.5 t.
Samsung Biologics Cybersecurity Score
Samsung Biologics Online and Social Media Presence
329 Twitter followers
Samsung Biologics has 329 Twitter Followers. The number of followers has increased 1.5% month over month and increased 3.5% quarter over quarter
Samsung Biologics's Trends
Samsung Biologics News and Updates
December 04, 2020
Samsung Biologics drives digital transformation with Plant 4 Virtual Showroom launch
INCHEON, South Korea, Dec. 4, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced the launch of a virtual showroom to provide key features and real-time construction updates of its recently announced Plant 4. The digital showcase also highlights various specs and services...
November 25, 2020
$ 25,497.26 MN Biopharmaceuticals Contract Manufacturing Market 2020: Top Companies Samsung Biologics, Inno Biologics Ventures, Ajinomoto, WuXi Biologics
The Biosimilars Segment by Product is expected to grow at A Fast Pace over the Forecast Period. Posted via Industry Today. Follow us on Twitter @IndustryToday
October 20, 2020
Samsung Biologics inks development partnership with Dinona for potential COVID-19 treatment
INCHEON, South Korea, Oct. 20, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a partnership agreement with biotech Dinona, further expanding its CDO capabilities to provide a full scope of its development services from cell line development, process development, to...
September 24, 2020
Samsung Biologics signs strategic partnership with Kanaph Therapeutics to develop treatment for retinal diseases
INCHEON, South Korea, Sept. 23, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and Kanaph Therapeutics have entered into a strategic partnership to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases. According to Kanaph Therapeutics, KNP-301 is...
September 17, 2020
Samsung Biologics signs development agreement with Panolos for solid tumor treatment
INCHEON, South Korea, Sept. 16, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors. Under this agreement, Samsung Biologics will provide a full scope of its...
August 11, 2020
Samsung Biologics to add fourth plant with growing demands
INCHEON, South Korea, Aug. 10, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today held an online press conference to announce its plans to break ground for a fourth plant within this year. This is part of its long-term strategy to maximize its operational efficiency and scale...
Samsung Biologics Frequently Asked Questions
When was Samsung Biologics founded?
Samsung Biologics was founded in 2011.
Who are Samsung Biologics key executives?
Samsung Biologics's key executives are John Rim, Dong Joong Kim and Seok Woo Jeong.
How many employees does Samsung Biologics have?
Samsung Biologics has 2,470 employees.
Who are Samsung Biologics competitors?
Competitors of Samsung Biologics include Pharmaron, WuXi Biologics and Kindeva Drug Delivery.
Where are Samsung Biologics offices?
Samsung Biologics has an office in.
How many offices does Samsung Biologics have?
Samsung Biologics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies